The FDA has approved Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%, plus the BF-RhodoLED lamp series for superficial basal cell carcinoma in adults, the first and only photodynamic therapy indicated for a skin cancer in the US.

In the supporting phase 3 trial, 66% of patients on Ameluz PDT (95 of 145) achieved complete clinical and histological response of the main target lesion at 12 weeks, compared with 5% on placebo-PDT (2 of 42).

Neal Bhatia, MD, says the approval gives dermatologists a nonsurgical option for patients with lesions in difficult-to-treat locations or surgical risk factors, using the same gel and lamp already deployed for actinic keratosis.

 approved Biofrontera's supplemental new drug application (sNDA) for Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%, implemented with the BF-RhodoLED lamp series, for the treatment of 

 in adults, making it the first photodynamic therapy (PDT) regimen the agency has cleared for a skin cancer.¹

Neal Bhatia, MD, director of clinical dermatology at Therapeutics Clinical Research in San Diego and chief medical editor of Practical Dermatology, discussed the September 14 approval with 

. Bhatia was asked about both the approval’s significance and some of the data surrounding the decision.

What the FDA's Approval of Ameluz PDT Means for Skin Cancer

The approval, granted a decade after Ameluz's original actinic keratosis (AK) indication, makes it the only topical PDT in the United States indicated for both a precancerous lesion and a skin malignancy.¹ It was supported by a multicenter, randomized, double-blind, vehicle-controlled phase 3 trial in 187 adults with histologically confirmed sBCC, in which 66% of patients treated with Ameluz PDT (95 of 145) achieved complete clinical and histological response of the main target lesion at 12 weeks, compared with 5% (2 of 42) on placebo-PDT.¹ 

 on the approval covers the regulatory background and trial data in more depth.²

"I don't want to ever say best option, but the easiest option,” Bhatia said. “People on anticoagulants, people on oxygen, there's always ways to think about, OK, where can I use something that doesn't involve surgery but still has efficacy of the tumor clearance? And I think this is where now we have a really good option in front of us.”

Bhatia said the indication gives dermatologists another nonsurgical route for patients whose lesions sit in difficult-to-treat locations, such as the pretibial surfaces, behind the ears, or near the eyelids, or who are poor surgical candidates because of anticoagulant or oxygen therapy. Mohs surgery remains the gold standard, he noted, alongside established options such as electrodesiccation and curettage and topical imiquimod.

He noted red-light PDT also treats the photo-damaged skin surrounding a tumor in addition to the lesion itself, a field effect he sees as an added benefit over surgical excision alone. Bhatia said he expects photodynamic therapy, delivered through the smaller BF-RhodoLED unit or the larger panel light, to become a standard fixture across dermatology practice settings.

Editor’s note: This transcript has been edited for grammar and clarity using artificial intelligence tools.

Biofrontera Inc. Biofrontera announces FDA approval of Ameluz Red Light PDT for the treatment of superficial basal cell carcinoma. Published September 14, 2026. Accessed September 14, 2026. 

https://www.globenewswire.com/news-release/2026/09/14/3361199/0/en/biofrontera-announces-fda-approval-of-ameluz-red-light-pdt-for-the-treatment-of-superficial-basal-cell-carcinoma.html

Smith T. Ameluz treatment becomes first FDA-approved PDT for skin cancer. HCPLive. Published September 14, 2026. Accessed September 16, 2026. 

https://www.hcplive.com/view/ameluz-treatment-becomes-first-fda-approved-pdt-skin-cancer

Videos

What does FDA approval of Ameluz PDT for superficial BCC mean for dermatology? Neal Bhatia, MD, weighs in on the first-of-its-kind decision.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

FDA News

Sten Rubertsson, MD, PhD, is a professor at the department of surgical sciences; anesthesiology, and intensive care at Uppsala University.

Immediate coronary angiography did not improve 30-day survival versus a deferred strategy in patients without an electrocardiogram (ECG) ST-elevation following out-of-hospital 

, according to new data from the DISCO trial.

Immediate Coronary Angiography Does Not Improve Survival Outcomes in Cardiac Arrest

European Society of Cardiology (ESC) Congress 2026

 in Munich, Germany, by Sten Rubertsson, MD, PhD, professor at the department of surgical sciences, anesthesiology, and intensive care at Uppsala University in Sweden.

“I think the findings of our study, these results, will be in support of the current ESC guidelines,” Rubertsson told 

 in an exclusive interview. “I think this issue is now officially solved, and that we need to move on to other issues of study to try and improve outcomes in patients with cardiac arrest.”

The Direct or Subacute Coronary Angiography in Out-of-hospital Cardiac Arrest (DISCO) trial was a prospective randomized open-label multicenter study with a registry follow-up including patients with out-of-hospital cardiac arrest without ST-elevation on their first ECG. The primary endpoint was 30-day survival, measured via telephone call or visit at 30 days. Secondary outcomes included survival with good neurological function, survival at discharge from ICU and at 6 months, and cardiac function, among others.

Patients were eligible for inclusion if they exhibited restoration of spontaneous circulation (ROSC) >20 minutes and were expected to undergo coronary angiography within 120 minutes from inclusion and randomization at hospital. Patients were excluded if they had obvious extracardiac genesis of cardiac arrest or ST-elevation, among other criteria.

A total of 1006 patients were enrolled and randomly assigned in a 1:1 ratio to either immediate coronary angiography or a deferred strategy, in which angiography was intended to be delayed for ≥72 hours. In cases of electrical or hemodynamic instability, angiography could be performed before 72 hours. In the immediate arm, percutaneous coronary intervention (PCI) was recommended on the presumed culprit lesion, while non-culprit lesions were not to be treated.

Ultimately, Rubertsson and colleagues saw no difference in the primary endpoint at 30 days (54.6% vs 53.6%; HR, 0.95; 95% CI, 0.74-1.21; 

 = .67). There was also no difference in survival at 180 days, and the team recorded no substantial differences related to neurological recovery based on the intervention used.

Rubertsson also discussed his belief regarding the utility of electrocardiography as a determiner for the immediacy of coronary angiography, due to its imperfect specificity in detecting the culprit lesion.

“It’s very difficult to say that you should use echocardiography as a reliable tool to decide, because when you’re right after cardiac arrest and you have to make the decision if you’re going to do an immediate coronary angiography, you have areas that are stunned due to the CPR – that doesn’t mean that they have an infarct in that area,” Rubertsson said. “I think that maybe further development with CT angiography could possibly be a better selection, but I don’t think that the sharpness of the tool is good enough for today.”

Editors’ Note: Rubertsson reports no relevant disclosures.

European Society of Cardiology. Should patients with an out-of-hospital cardiac arrest and without an ECG ST-elevation receive immediate coronary angiography? August 31, 2026. Accessed September 16, 2026. 

https://www.escardio.org/news/press/press-releases/should-patients-with-an-out-of-hospital-cardiac-arrest-and-without-an-ecg-st-elevation-receive-immediate-coronary-angiography/

Uppsala University. Direct or Subacute Coronary Angiography in Out-of-hospital Cardiac Arrest (DISCO). ClinicalTrials.gov Identifier: NCT02309151. Updated April 8, 2026. Accessed September 16, 2026. 

https://clinicaltrials.gov/study/NCT02309151

Sten Rubertsson, MD, PhD, discusses the results of the DISCO study, which compared immediate to deferred angiography in patients without ST-elevation following cardiac arrest.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Consultant Respiratory Physician and the Clinical Lead for the Interstitial Lung Disease Unit at the Royal Brompton Hospital. He is Professor of Practice (Respiratory Medicine) in the Cardiorespiratory Interface Section at the National Heart and Lung Institute, Imperial College.

A post hoc quantitative CT (QCT) analysis of the phase 2a ENV-IPF-101 trial found that taladegib (ENV-101), an oral hedgehog pathway inhibitor, increased lung volume and reduced imaging markers of interstitial lung disease (ILD) extent in patients with 

, according to Peter George, MD, PhD, consultant respiratory physician and clinical lead for interstitial lung disease at Royal Brompton Hospital. George discussed the late-breaking abstract, presented at the 

European Respiratory Society (ERS) Congress 2026

 in Barcelona, Spain, held September 5 to 9, in an interview with 

. George is also senior medical director for respiratory at Brainomix, the company whose e-Lung algorithm was used in this analysis.

Taladegib Boosts Lung Volume, Reduces Fibrosis on Quantitative CT

The parent 12-week trial previously showed taladegib improved percent-predicted forced vital capacity (FVC) by a mean of 1.9% from baseline versus a 1.3% decline with placebo.

 In the new analysis, applying Brainomix's e-Lung algorithm to baseline and week-12 high-resolution CT scans from 34 patients (15 taladegib, 19 placebo), taladegib was associated with an increase in e-Lung volume compared with placebo (+204 mL vs −60 mL; 

 = .003) and a reduction in total disease extent, a measure of overall ILD burden (mean change, −2.9% vs +1.0%; 

 The taladegib group also showed a significant reduction in reticulovascular score, a marker of total fibrosis severity (−0.7% vs +0.5%; 

 = .04), a trend toward reduced weighted reticulovascular score (WRVS), a measure of peripheral fibrosis (−0.5% vs +0.6%; 

 = .1), and a significant reduction in pulmonary vascular volume (−0.35% vs +0.02%; 

George said the taladegib and placebo groups were well matched at baseline, with WRVS of 15.5% and 14.2%, respectively, and that the taladegib group's slightly higher baseline severity, given that a WRVS above 15% has been linked in prior work to accelerated lung function decline, strengthens rather than undermines confidence in the findings. He also pointed to concordant signals between 2 independent QCT platforms, the UCLA Voyant algorithm used in the original analysis and Brainomix e-Lung used here, as evidence supporting a genuine drug effect rather than a technology-specific artifact.

George was direct about the disease being addressed. “IPF is a terrible disease. It's a disease that is associated with inexorable lung function decline, progressive symptoms, and certain death, and that is the reality of what is really a very severe disease,” he said.

He cautioned that this remains a small, post hoc analysis from a 12-week phase 2a trial, and that phase 2a signals have historically not always replicated in larger studies; he said the field awaits data from the ongoing phase 2b WHISTLE-PF trial before drawing firmer conclusions. Still, he said the combination of lung function and imaging signals adds confidence heading into that readout, and that quantitative CT could increasingly inform both trial go/no-go decisions and clinical treatment choices in IPF.

George’s disclosures include Boehringer Ingelheim, AstraZeneca, Daiichi Sankyo, Avalyn, and GSK, and he is senior medical director for respiratory at Brainomix.

Maher TM, Goldin JG, Hood J, et al. Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial. 

 2025;13(11):1001-1010. doi:10.1016/S2213-2600(25)00239-5

George P, Deveraj A, DiFrancesco A, et al. Treatment with taladegib results in increased lung volume and regression of markers of ILD: a phase 2a post hoc CT analysis using Brainomix e-Lung. Late-breaking abstract presented at: European Respiratory Society (ERS) Congress 2026; September 5-9, 2026; Barcelona, Spain.

George, of Royal Brompton Hospital discusses a phase 2a post hoc analysis showing increases in lung volume and reduced ILD.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Pulmonary Fibrosis

Taladegib Improves Lung Fibrosis on Quantitative CT: Peter George, MBBS, PhD

This is a deep dive into one segment of a recent episode of 

Kidney Compass: Navigating Clinical Trials

, HCPLive's podcast co-hosted by Shikha Wadhwani, MD, and Brendan Neuen, MBBS, PhD. In this episode, Neuen steps out of his usual co-host role to join as a guest, discussing the FIND-CKD trial results he presented at the European Renal Association (ERA) Congress.

Inside FIND-CKD: Can Finerenone Pair With Immunosuppression in GN?

Finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), doesn't target the immune mechanisms driving 

 and according to Brendan Neuen, MBBS, PhD, that's exactly the point. The FIND-CKD trial excluded patients treated with immunosuppression in the 6 months prior to enrollment, a design choice Neuen said reflected the conservatism of the trial's 2020 design rather than a signal against combining the two treatment approaches.

"We're not reducing Gd-IgA1 with finerenone," Brendan Neuen, MBBS, PhD, told HCPLive. "That's not the point of the drug."

Why FIND-CKD Excluded Recent Immunosuppression

"We weren't necessarily surprised that the treatment effect was consistent across, regardless of the type of kidney disease," Neuen said. "We know that mineralocorticoid receptor antagonism is a final common pathway across many forms of kidney disease, and so if you think about it that way, it's not surprising that the benefits are there across different forms of kidney disease, including GN."

Neuen said the immunosuppression exclusion criterion was a product of its era. "This was back in 2020, as I like to remind people, before DAPA-CKD," he said. "If we'd done it again, perhaps I would. I mean, we would have liked to, and I think we're being much more inclusive with kidney outcome trials now."

A More Inclusive Approach in Current Trial Design

Neuen described how his approach to eligibility criteria has shifted in trials he has since been involved in. "If people have a kidney disease requiring immunological therapy, so long as that treatment is stable, and investigators don't anticipate a relapse or something else, then it's worth including those patients in, because it allows us to be more inclusive and our results are more generalizable," he said.

He noted the tradeoff cuts both ways. "If you do include a group like that in whom the treatment might not work and that muddies the overall result, then we're not really advancing care for anyone. So it's a fine balance to walk," Neuen said.

The Case for Combining Finerenone With Immunosuppressive Therapy

From a mechanistic standpoint, Neuen sees no barrier to using finerenone alongside immunological treatment. "If you just think about the way that our drugs work, and what guidelines say, you know, KDIGO for IgA nephropathy: target the underlying immunological problem and the downstream consequences of IgA-mediated nephron loss," he said. "I see no reason why we shouldn't be doing these together simultaneously with a SGLT2 inhibitor and an MRA, because they're targeting completely different pathways and complementary pathways."

Neuen's framing aligns with the 2025 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of IgA Nephropathy (IgAN), which explicitly recommends combining anti-inflammatory and antifibrotic agents with therapies that target IgA immune-complex formation. The guideline notes that the optimal sequencing of these combinations still needs to be established through trials, a gap Neuen's comments suggest FIND-CKD and future analyses are beginning to address.

Neuen said forthcoming data will help clarify how finerenone exerts its protective effect in IgA nephropathy specifically. "Later this year, at another meeting, I'll be presenting some of the data specifically in the IgAN cohort, helping us to understand how finerenone is exerting its kidney disease protective effects," he said. "No surprises: it's probably not targeting the immunological aspect of the disease."

Layering and Sequencing as the Next Frontier

Neuen framed the immunological and non-immunological pathways as complementary rather than competing. "The point of the drug is to address the common final pathways that are not unique to IgAN, but all forms of kidney disease, and we can do that in parallel with disease-modifying therapies now," he said.

He pointed to layering and sequencing as an emerging area of focus. "I think that is the really exciting part of this whole conversation, which is how do we layer these therapies, how do we sequence them," Neuen said, adding that the topic warrants further discussion beyond this conversation.

Editors' Note: Disclosures for Wadhwani include Boehringer Ingelheim, Calliditas Therapeutics, GSK, Otsuka Pharmaceutical Co., Travere Therapeutics, and others. Disclosures for Neuen include AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, and others.

Heerspink HJL, Neuen BL, Agarwal R, et al. Finerenone in persons with chronic kidney disease without diabetes. 

Floege J, Barratt J, Cook HT, et al. Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). 

Brendan Neuen explains why finerenone's mechanism supports combining it with immunosuppressive therapy in glomerulonephritis.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

John Ostrominski, MD, is a fellow in cardiovascular medicine and an obesity medicine specialist at Brigham and Women’s Hospital.

 are not impacted by the presence of ≥1 cardio-kidney-metabolic (CKM) condition at baseline, according to a secondary analysis of FINEARTS-HF.

Finerenone’s Efficacy in HF Unaffected by Concomitant CKM Components

 in Munich, Germany, by John Ostrominski, MD, a fellow in cardiovascular medicine and an 

 medicine specialist at Brigham and Women’s Hospital.

“This is really a snapshot view of those who were eligible for the trial at randomization, so we’re a bit limited in what we can say in terms of how often or how prominently these conditions were drivers of the condition,” Ostrominski told 

 in an exclusive interview. “But I do think it has implications for the causality of at least HFpEF and the breadth of the view that’s needed to really engage in comprehensive care in this population.”

FINEARTS-HF was a randomized, double-blind, international, multicenter, parallel-group, event-driven trial comparing finerenone to placebo in patients with HF with preserved ejection fraction (HFpEF). Eligible patients were required to be ≥40 years old with symptomatic HF, a left ventricular ejection fraction (LVEF) of ≥40%, evidence of 

, and elevated natriuretic peptide levels.

Eligible patients were randomly assigned in a 1:1 ratio to either finerenone or matching placebo on top of standard therapy. Finerenone was administered at a maximum of 20 mg or 40 mg once daily, depending on baseline estimated glomerular filtration rate (eGFR). The study’s primary outcome was a composite of total worsening HF events and cardiovascular death. Secondary outcomes included total worsening HF events, change from baseline in the total symptom score from the Kansas City Cardiomyopathy Questionnaire (KCCQ), and improvement in New York Heart Association (NYHA) functional class by month 12.

A total of 6016 patients were enrolled in the trial. Mean (+/- standard deviation [SD]) LVEF was 53 +/- 8%, and 69.1% of patients were in NYHA functional class II. 1219 patients were enrolled during or ≤7 days after an HF event. At baseline, 84.9% of patients were receiving beta-blockers, 35.9% were receiving angiotensin-converting enzyme inhibitors, 35% were receiving angiotensin-receptor blockers, 8.5% were receiving angiotensin receptor-neprilysin inhibitors, and 13.6% were receiving SGLT2 inhibitors.

Over a median follow-up of 32 months, investigators recorded 1083 primary-outcome events among 624 of 3003 patients in the finerenone arm. Another 1283 primary-outcome events occurred in 719 of the 2998 patients assigned to receive placebo (rate ratio [RR], 0.84; 95% CI, 0.74 to 0.95; 

 = .007). The total number of worsening HF events was 842 in the finerenone arm versus 1024 in the placebo arm (RR, 0.82; 95% CI, 0.71 to 0.94; 

In the present analysis, Ostrominski and colleagues examined the same patient population for the presence of ≥1 aspect of CKM syndrome. These included cardiovascular disease, defined as a history of 

atherosclerotic cardiovascular disease (ASCVD)

, or metabolic disease, defined as either obesity, 

, or history of metabolic dysfunction-associated steatotic liver disease.

Of the 6001 patients who ultimately completed FINEARTS-HF, 5977 had ≥1 concomitant CKM component. Of these, 619 had 0-1 overlapping components, 2170 had 2 overlapping components, and 3212 had 3 overlapping components. Those with 2 (adjusted RR, 1.32; 95% CI, 1.02-1.72) and 3 (adjusted RR, 2.58; 95% CI, 2.01-3.32) components saw incrementally higher rates of the primary composite outcome of cardiovascular death and total HF events after a median follow-up of 2.7 years. However, the benefits of finerenone on cardiovascular death and HF events appeared consistent irrespective of the number of CKM components.

“I suspect that the broad message here is that this profile, these intersectional diseases, is very much consistent with how we’re increasingly viewing HFpEF and HFrEF as a disease that is really mediated, but also sort of feeding back into these general profiles and pathways of multiple long-term conditions,” Ostrominski said. “This message has important implications for how we think about the disease, but there are certain things that we just didn’t quite have access to in the trial, and so it’s important to acknowledge these limitations.”

Editors’ Note: Ostrominski reports receiving grant support from the National Institutes of Health.

Ostrominski J. Cardiovascular-kidney-metabolic overlap and finerenone in heart failure: insights from the FINEARTS-HF Trial. Presented at the European Society of Cardiology (ESC) Congress 2026, Munich, Germany. August 28-31, 2026.

Pabon MA, Vardeny O, Vaduganathan M, et al. Finerenone in heart failure with improved ejection fraction. 

John Ostrominski, MD, discusses his analysis of the FINEARTS-HF trial, which showed finerenone’s improvements despite CKD, ASCVD, and/or metabolic disease.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Chronic Kidney Disease

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Type 2 Diabetes

Wynne Armand, MD, from Massachusetts General Hospital.

Articles

In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Seasonal Allergy

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

What Wildfire Smoke Does to Allergic Skin Disease, With Wynne Armand, MD

In this Q&A, Leon Kircik, MD, discusses challenging watch-and-wait for molluscum contagiosum with berdazimer gel, 10.3%, at LEADderm 2026.

Q&A: Berdazimer Gel and the Case Against 'Watch-and-Wait' for Molluscum

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

New ASH guidelines recommend higher ferritin thresholds to improve the diagnosis of iron deficiency across key populations.

Hematology

Anemia

ASH Issues New Ferritin Thresholds for Iron Deficiency Diagnosis

Alysse Wurcel, MD, of Boston Medical Center

In this Q&A, Alysse Wurcel, MD, translates qualitative barriers into 8 concrete tactics healthcare practices can use to expand penicillin allergy delabeling.

8 Strategies to Improve Access to Penicillin Allergy Delabeling

Director, Center for Lung Analytics and Imaging Research (CLAIR), Endowed Professor of Airways Disease at the University of Alabama at Birmingham School of Medicine

Bhatt also discusses how these findings inform the choice between dupilumab and mepolizumab under GOLD 2026.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Dupilumab Cuts COPD Exacerbations Across Seasons, Smoking Status: Surya Bhatt, MD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for 

. He is also the executive producer of two podcasts: 

. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

In this feature, several leaders in the dermatology space were asked how far we have come and where the field is headed in precision medicine.

Where is Precision Medicine Today in Dermatology?

Abigail Brooks is a strategic content lead overseeing 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Boehringer Ingelheim halted EASi-KIDNEY after a DMC found data did not support a meaningful clinical benefit on the trial's primary endpoint.

Vicadrostat EASi-KIDNEY Trial Discontinued for Lack of Benefit in CKD

Professor and Pneumologist, University Hospitals Leuven 

Wuyts, of University Hospitals Leuven discusses interim FIBRONEER-ON open-label extension data showing nerandomilast's favorable safety profile.

FIBRONEER-ON: Nerandomilast's Durable IPF, PPF Safety, With Wim Wuyts, MD, PhD

Jonathan Piccini, MD, is the director of cardiac electrophysiology at Duke University Health System.

Jonathan Piccini, MD, discusses his presentation at ESC 2026 discussing the potential benefits of catheter ablation in concomitant HFpEF and AF.

Arrhythmia

Catheter Ablation Improves, May Reverse HFpEF Symptoms in Patients With AF

BEACON-HCC offers a new approach to HCC treatment allocation, with key differences from the updated BCLC framework.

Latest News

What the FDA's Approval of Ameluz PDT Means for Skin Cancer

Immediate Coronary Angiography Does Not Improve Survival Outcomes in Cardiac Arrest

Taladegib Improves Lung Fibrosis on Quantitative CT: Peter George, MBBS, PhD

Inside FIND-CKD: Can Finerenone Pair With Immunosuppression in GN?

Finerenone’s Efficacy in HF Unaffected by Concomitant CKM Components